Back to search
FDAFDA · Food and drugs·Recall number D-1091-2023

Helix Tri-Active Therapy Cream (Camphor 3.2%, Menthol 7.4%, Methyl salicylate 12.5%), packaged in a) 3 fl. oz. roll-on (NDC 30775-052-03) and b) 4 fl. oz. tube (NDC 30775-052-04) Parker Laboratories, Inc. 286 Eldridge Road, Fairfield, NJ 07004

Published August 30, 2023 · Recall initiated: August 2, 2023

Summary

FDA records drug Class II recall D-1091-2023, published August 30, 2023 and initiated August 2, 2023. Recalling firm: Parker Laboratories, Inc.; Status: Terminated; Reported quantity: 8; Lot: Lot #: a) A1221010, Exp. Date 12/9/2023, b) A1221011, Exp date 12/9/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Parker Laboratories, Inc.
Distributor
Nationwide within the United States, Singapore, Korea and Hong Kong
Lot
Lot #: a) A1221010, Exp. Date 12/9/2023, b) A1221011, Exp date 12/9/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Helix Tri-Active Therapy Cream (Camphor 3.2%, Menthol 7.4%, Methyl salicylate 12.5%), packaged in a) 3 fl. oz. roll-on (NDC 30775-052-03) and b) 4 fl. oz. tube (NDC 30775-052-04) Parker Laboratories, Inc. 286 Eldridge Road, Fairfield, NJ 07004 recalled?

Yes. FDA published recall D-1091-2023 on August 30, 2023. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail